News
MDXG
7.29
-2.28%
-0.17
CASSAVA SCIENCES INC: RENEWAL OF QUARTERLY ANALYST CALLS
Reuters · 2d ago
MIMEDX to Host Second Quarter 2024 Operating and Financial Results Conference Call on July 31
MiMedx Group, Inc. Will report its operating and financial results for the second quarter ended June 30, 2024 after the market close on Wednesday, July 31, 2024. The company will host a webcast and conference call to review its results on the same day.
Barchart · 2d ago
Weekly Report: what happened at MDXG last week (0708-0712)?
Weekly Report · 4d ago
Weekly Report: what happened at MDXG last week (0701-0705)?
Weekly Report · 07/08 09:49
Analyst Bullish On MiMedx's Rapid Growth In $4B Woundcare Market With Innovative Skin Substitutes
Cantor Fitzgerald has initiated coverage on MiMedx Group Inc. The company is a provider of a product portfolio for applications in wound care, burn, and surgical recovery. MIMEDX’s technologies target a $3.9 billion market. Cantor initiates with an Overweight rating and a price target of $11.
Benzinga · 07/02 18:32
Cantor starts MiMedx at overweight, cites valuation, product offerings
Cantor Fitzgerald starts MiMedx at overweight, cites valuation, product offerings. The investment bank has a $11 price target for the stock. The company's product portfolio is "differentiated and protected," Cantor says. MiMedX Group, Inc. Is a wound care product maker.
Seeking Alpha · 07/02 18:15
MiMedx Group Price Target Announced at $11.00/Share by Cantor Fitzgerald
Dow Jones · 07/02 10:56
MiMedx Group Initiated at Overweight by Cantor Fitzgerald
Dow Jones · 07/02 10:56
Cantor Fitzgerald Initiates Coverage On MiMedx Group with Overweight Rating, Announces Price Target of $11
Benzinga · 07/02 10:46
Weekly Report: what happened at MDXG last week (0624-0628)?
Weekly Report · 07/01 09:49
Craig-Hallum Gives a Buy Rating to MiMedx Group (MDXG)
TipRanks · 06/28 13:06
MiMedx appoints Kim Moller as chief commercial officer
MiMedx appoints Kim Moller as chief commercial officer. Moller has been serving as the company’s Senior Vice President, Sales since August 2020. MiMedx Group, Inc. (NASDAQ:MDXG) stock is up 1.5%.
Seeking Alpha · 06/26 20:07
MIMEDX ANNOUNCES THE APPOINTMENT OF KIM MOLLER TO CHIEF COMMERCIAL OFFICER
Reuters · 06/26 20:01
Press Release: MIMEDX Announces the Appointment of Kim Moller to Chief Commercial Officer
Dow Jones · 06/26 20:01
Weekly Report: what happened at MDXG last week (0617-0621)?
Weekly Report · 06/24 09:52
Weekly Report: what happened at MDXG last week (0610-0614)?
Weekly Report · 06/17 09:49
Weekly Report: what happened at MDXG last week (0603-0607)?
Weekly Report · 06/10 09:50
Weekly Report: what happened at MDXG last week (0527-0531)?
Weekly Report · 06/03 09:51
Weekly Report: what happened at MDXG last week (0520-0524)?
Weekly Report · 05/27 09:52
Analysts Are Bullish on Top Healthcare Stocks: Guardant Health (GH), Durect (DRRX)
TipRanks · 05/22 13:00
More
Webull provides a variety of real-time MDXG stock news. You can receive the latest news about Mimedx Group Inc through multiple platforms. This information may help you make smarter investment decisions.
About MDXG
MiMedx Group, Inc. is a placental biologics company. The Company is engaged in developing and distributing placental tissue allografts with patent-protected, processes for multiple sectors of healthcare. Its product portfolio categories include Wound Care Products, and Surgical and Other Products. Its Wound Care Products include EPIFIX, EPICORD and EPIEFFECT, which are all marketed for external use, such as in advanced wound care applications. Its Surgical and Other product offering includes AMNIOFIX, AMNIOCORD and AMNIOEFFECT, which are positioned for use in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. The Company's platform technologies include tissue allografts derived from the human placental membrane, tissue allografts derived from the human umbilical cord, and a particulate extracellular matrix derived from the human placental disc.